GlassScriptPhysician profile
Marlys A Bitner
NPI 1528172095
$8,223.88
in general payments reported to CMS, 2019-2025
44 companies · $899 in 2025
The $899 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,539 · 2022: $2,683 · 2023: $2,294 · 2024: $809 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.14 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,698.95 | 2021-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,461.25 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.90 | 2021-2023 | Ofev, Stiolto Respimat |
| Abbott Laboratories | $654.37 | 2021-2025 | Freestyle Libre, Mitraclip, Cardiomems |
| Pfizer INC. | $523.36 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $432.10 | 2021-2025 | Dupixent, Evkeeza |
| Genzyme Corporation | $330.77 | 2022-2023 | |
| Amgen INC. | $301.69 | 2021-2025 | Repatha, Tezspire |
| Actelion Pharmaceuticals US, INC. | $220.58 | 2022-2025 | Uptravi, Opsumit |
| Abbvie INC. | $213.05 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $164.35 | 2025 | Amvuttra |
| Csl Behring | $133.35 | 2021-2024 | Kcentra |
| Insmed, INC. | $108.18 | 2022-2024 | Arikayce |
| Grifols USA, LLC | $106.69 | 2022-2023 | Prolastin-C Liquid |
| Genentech USA, INC. | $97.46 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlys Bitner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.